ROTH OTC
PharmaRoth Labs, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -90.0%
1Y: -90.0%
3Y: -99.8%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$182K
-31.1% ▼
Gross Profit
$73K
-32.8% ▼
Operating Income
-$92K
+60.7% ▲
Net Income
-$92K
+60.7% ▲
EPS (Diluted)
$-0.00
+66.7% ▲
EBITDA
-$92K
+60.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $154K | $529K | $87K | $263K | $182K |
| YoY Growth | +0.0% | +243.8% | -83.6% | +202.9% | -31.1% |
| Cost of Revenue | $120K | $213K | $60K | $155K | $109K |
| Gross Profit | $34K | $316K | $27K | $108K | $73K |
| Gross Margin | 22.2% | 59.8% | 31.0% | 41.0% | 40.0% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $461K | $609K | $397K | $341K | $164K |
| Operating Expenses | $461K | $609K | $397K | $341K | $164K |
| Operating Income | -$427K | -$293K | -$370K | -$233K | -$92K |
| Operating Margin | -277.3% | -55.3% | -425.4% | -88.4% | -50.4% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$427K | -$293K | -$370K | -$233K | -$92K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$425K | -$291K | -$370K | -$233K | -$92K |
| Net Margin | -276.3% | -55.0% | -425.1% | -88.4% | -50.4% |
| EPS (Diluted) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| EBITDA | -$425K | -$292K | -$370K | -$233K | -$92K |
| Shares Outstanding | 219M | 281M | 322M | 365M | 380M |